Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261503 | 1.00 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL598582 | 0.88 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4267167 | 0.88 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL599577 | 0.86 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4258214 | 0.86 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4263039 | 0.85 | CACNA2D1 (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL598548 | 0.85 | CACNA2D1 (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL12896244 | 0.84 | CTSS (0.49) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1047904 | 0.84 | CTSS (0.49) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4265465 | 0.83 | CACNA2D1 (0.38) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086530-A1 | USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS | Xenoport, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | XENOPORT, INC. | 2008-08-07 | — | — | US | claimed |
| EP-1928450-A2 | TREATING PREMATURE EJACULATION USING GABAPENTIN AND PREGABALIN PRODRUGS | Xenoport, Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2008060572-A1 | USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS | XENOPORT, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2007027477-A2 | TREATING VULVODYNIA USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| WO-2007027476-A2 | TREATING PREMATURE EJACULATION USING GABAPENTIN AND PREGABALIN PRODRUGS | XENOPORT, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | XENOPORT, INC. | 2007-03-01 | — | — | US | claimed |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | XENOPORT, INC. | 2007-03-01 | — | — | US | claimed |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | XENOPORT INC. | 2012-02-16 | — | — | US | disclosed |
| US-8114909-B2 | Utilizing extended release forms with reduced rates of systemic clearance; eliminating significant side effects | XENOPORT, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100166825-A1 | TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7700652-B2 | Treating urinary incontinence using prodrugs of GABA analogs | XENOPORT, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2101752-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | Xenoport, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2086530-A1 | USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS | Xenoport, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20050209319-A1 | Treatment of local pain | XENOPORT, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050192353-A1 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2005-09-01 | — | — | US | disclosed |
| US-20050090550-A1 | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs | ARBOR PHARMACEUTICALS, LLC | 2005-04-28 | — | — | US | disclosed |
| WO-2005025562-A1 | TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20040254246-A1 | Gabapentin, pregabalin | XENOPORT, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004089289-A2 | TREATING OR PREVENTING HOT FLASHES USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | GABRB1, GABBR1, GABRB2 | CACNA2D1 298/4885CACNB3 136/4885CACNA1C 43/4885 |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | GABRB1, GABBR1, GABRB3 | CACNA2D1 1560/4885CACNB3 289/4885CACNA1C 695/4885 |
| US-20040254246-A1 | Gabapentin, pregabalin | GABRB2, GABRB3, GABRB1 | CACNA2D1 361/4885CACNB3 37/4885CACNA1C 42/4885 |
| US-20050209319-A1 | Treatment of local pain | GABBR1, GABBR2, GABRB2 | CACNA2D1 517/4885CACNB3 18/4885CACNA1C 57/4885 |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | GABBR1, GABRE, GABRB2 | CACNA2D1 948/4885CACNB3 251/4885CACNA1C 364/4885 |
| US-20100166825-A1 | TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS | GABBR2, GABRB1, GABBR1 | CACNA2D1 2414/4885CACNB3 613/4885CACNA1C 878/4885 |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | GABBR1, GABBR2, GABRB3 | CACNA2D1 869/4885CACNB3 107/4885CACNA1C 156/4885 |
| US-20050192353-A1 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | GABRB1, GABBR2, GABARAPL1 | CACNA2D1 703/4885CACNB3 51/4885CACNA1C 59/4885 |
| US-20050090550-A1 | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs | GABBR2, GABRB1, GABBR1 | CACNA2D1 2414/4885CACNB3 613/4885CACNA1C 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.